Efficacy of Immune Checkpoint Inhibitors in Advanced Large Cell Neuroendocrine Carcinoma of the Lung: A Single‑institution Experience

Overview

Journal Oncol Lett

Specialty Oncology

Date 2024 Feb 15

PMID 38357477

Authors

Ningning Yan

Sanxing Guo

Ziheng Zhang

Shujing Shen

Xingya Li

Affiliations

Soon will be listed here.

Abstract

Large cell neuroendocrine carcinoma (LCNEC) is a rare and highly invasive lung cancer subtype with an overall poor prognosis. Due to its low incidence rate and unusual pathological features, the clinical management of LCNEC remains controversial. The present study aimed to assess the effect of immune checkpoint inhibitors (ICIs) on treatment response and survival outcomes in patients with advanced LCNEC. The clinical data from 148 patients with LCNEC treated with ICIs at The First Affiliated Hospital of Zhengzhou University (Zhengzhou, China) between January 2019 and September 2021 were retrospectively analyzed. Kaplan-Meier and multivariable Cox regression analyses were used to evaluate associations between clinicopathological variables and patient outcomes. Patients treated with ICIs demonstrated extended median overall survival (mOS) times [23.5 months; 95% confidence interval (CI), 18.524-28.476] compared with patients who did not receive ICIs (11.2 months; 95% CI, 4.530-18.930) (P<0.001). Univariate analysis revealed that histological subtype (P=0.043), lymph node metastases (P=0.032) and number of metastatic organs (P=0.009) were associated with a poor prognosis. The heterogeneity of pathological components was associated with prognosis, and the mOS time was shorter for mixed LCNEC than that for pure LCNEC (P=0.043). The median progression-free survival (mPFS) (9.78 vs. 9.37 months; P=0.82) and mOS (20.70 vs. 25.79 months; P=0.181) times showed no significant association with regard to different regimens of immuno-based combination therapy (chemotherapy combined with ICIs vs. anti-angiogenic agents combined with ICIs). Poor Eastern Cooperative Oncology Group performance status score (P=0.04), multiple organ metastases (P=0.02) and high cancer antigen 125 levels (P=0.01) were independent risk factors of a poor prognosis. The present findings offer valuable insights into potential prognostic markers and highlight the favorable impact of ICIs on OS in advanced LCNEC. Prospective clinical studies are required to validate the therapeutic value of ICIs in LCNEC.

Citing Articles

Efficacy and safety of immunotherapy plus chemotherapy in advanced or metastatic pulmonary large-cell neuroendocrine carcinoma.

Li R, Zhang H, Li Y, Yao X, Dong X, Xu Y Discov Oncol. 2025; 16(1):316.

PMID: 40085398 DOI: 10.1007/s12672-025-02071-8.

References

Miyoshi T, Umemura S, Matsumura Y, Mimaki S, Tada S, Makinoshima H . Genomic Profiling of Large-Cell Neuroendocrine Carcinoma of the Lung. Clin Cancer Res. 2016; 23(3):757-765. DOI: 10.1158/1078-0432.CCR-16-0355. View

Dudnik E, Kareff S, Moskovitz M, Kim C, Liu S, Lobachov A . Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung. J Immunother Cancer. 2021; 9(2). PMC: 7893659. DOI: 10.1136/jitc-2020-001999. View

Agar C, Geier M, Leveiller G, Lamy R, Bizec J, Tiercin M . Brief Report on the Efficacy of Nivolumab in Patients With Previously Treated Advanced Large-Cell Neuroendocrine Cancer of the Lung. JTO Clin Res Rep. 2021; 2(4):100129. PMC: 8474479. DOI: 10.1016/j.jtocrr.2020.100129. View

Fujiwara Y, Sekine I, Tsuta K, Ohe Y, Kunitoh H, Yamamoto N . Effect of platinum combined with irinotecan or paclitaxel against large cell neuroendocrine carcinoma of the lung. Jpn J Clin Oncol. 2007; 37(7):482-6. DOI: 10.1093/jjco/hym053. View

Hanna N, Robinson A, Temin S, Baker Jr S, Brahmer J, Ellis P . Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update. J Clin Oncol. 2021; 39(9):1040-1091. DOI: 10.1200/JCO.20.03570. View

Rossi G, Cavazza A, Marchioni A, Longo L, Migaldi M, Sartori G . Role of chemotherapy and the receptor tyrosine kinases KIT, PDGFRalpha, PDGFRbeta, and Met in large-cell neuroendocrine carcinoma of the lung. J Clin Oncol. 2005; 23(34):8774-85. DOI: 10.1200/JCO.2005.02.8233. View

Yang Q, Xu Z, Chen X, Zheng L, Yu Y, Zhao X . Clinicopathological characteristics and prognostic factors of pulmonary large cell neuroendocrine carcinoma: A large population-based analysis. Thorac Cancer. 2019; 10(4):751-760. PMC: 6449250. DOI: 10.1111/1759-7714.12993. View

Peng L, Wang Y, Liu F, Qiu X, Zhang X, Fang C . Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors. Cancer Immunol Immunother. 2020; 69(9):1813-1822. PMC: 7413896. DOI: 10.1007/s00262-020-02585-w. View

Ferrara M, Stefani A, Simbolo M, Pilotto S, Martini M, Lococo F . Large Cell Neuro-Endocrine Carcinoma of the Lung: Current Treatment Options and Potential Future Opportunities. Front Oncol. 2021; 11:650293. PMC: 8081906. DOI: 10.3389/fonc.2021.650293. View

10.

Travis W, Brambilla E, Nicholson A, Yatabe Y, Austin J, Beasley M . The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification. J Thorac Oncol. 2015; 10(9):1243-1260. DOI: 10.1097/JTO.0000000000000630. View

11.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

12.

Sherman S, Rotem O, Shochat T, Zer A, Moore A, Dudnik E . Efficacy of immune check-point inhibitors (ICPi) in large cell neuroendocrine tumors of lung (LCNEC). Lung Cancer. 2020; 143:40-46. DOI: 10.1016/j.lungcan.2020.03.008. View

13.

Wakeam E, Adibfar A, Stokes S, Leighl N, Giuliani M, Varghese Jr T . Defining the role of adjuvant therapy for early-stage large cell neuroendocrine carcinoma. J Thorac Cardiovasc Surg. 2019; 159(5):2043-2054.e9. DOI: 10.1016/j.jtcvs.2019.09.077. View

14.

Welter S, Aigner C, Roesel C . The role of surgery in high grade neuroendocrine tumours of the lung. J Thorac Dis. 2017; 9(Suppl 15):S1474-S1483. PMC: 5690951. DOI: 10.21037/jtd.2017.01.60. View

15.

Le Treut J, Sault M, Lena H, Souquet P, Vergnenegre A, Le Caer H . Multicentre phase II study of cisplatin-etoposide chemotherapy for advanced large-cell neuroendocrine lung carcinoma: the GFPC 0302 study. Ann Oncol. 2013; 24(6):1548-52. DOI: 10.1093/annonc/mdt009. View

16.

Postmus P, Kerr K, Oudkerk M, Senan S, Waller D, Vansteenkiste J . Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4):iv1-iv21. DOI: 10.1093/annonc/mdx222. View

17.

Zhang J, Li Y, Yan L, Zhu Z, Dong X, Chu Q . Disparity in clinical outcomes between pure and combined pulmonary large-cell neuroendocrine carcinoma: A multi-center retrospective study. Lung Cancer. 2019; 139:118-123. DOI: 10.1016/j.lungcan.2019.11.004. View

18.

Corbett V, Arnold S, Anthony L, Chauhan A . Management of Large Cell Neuroendocrine Carcinoma. Front Oncol. 2021; 11:653162. PMC: 8432609. DOI: 10.3389/fonc.2021.653162. View

19.

Gu J, Gong D, Wang Y, Chi B, Zhang J, Hu S . The demographic and treatment options for patients with large cell neuroendocrine carcinoma of the lung. Cancer Med. 2019; 8(6):2979-2993. PMC: 6558599. DOI: 10.1002/cam4.2188. View

20.

Moon J, Choi S, Kim T, Lee J, Pyo J, Kim Y . Clinical features and treatment outcomes of resected large cell neuroendocrine carcinoma of the lung. Radiat Oncol J. 2022; 39(4):288-296. PMC: 8743456. DOI: 10.3857/roj.2021.00423. View